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Humoral immune deficiencies have been associated with noninfectious disease complications including autoimmune cytopenias
andpulmonarydisease.Hereinwepresentapatientwhounderwentsplenectomyforautoimmunecytopeniasandsubsequentlywas
diagnosed with humoral immune deficiency in the context of recurrent infections. Immunoglobulin analysis prior to initiation of
intravenousimmunoglobulin (IVIG)therapy was notableforlowage-matched serumlevels of IgA(11mg/dL),IgG2 (14mg/L),and
IgG4 (5mg/L) with a preserved total level of IgG. Flow cytometry was remarkable for B cell maturation arrest at the IgM+/IgD+
stage. Selective screening for known primary immune deficiency-causing genetic defects was negative. The disease course was
uniquely complicated by the development of pulmonary arteriovenous malformations (AVMs), ultimately requiring bilateral lung
transplantation in 2012. This is a patient with humoral immune deficiency that became apparent only after splenectomy, which
argues for routine immunologic evaluation prior to vaccination and splenectomy. Lung transplantation is a rare therapeutic
endpoint and to our knowledge has never before been described in a patient with humoral immune deficiency for the indication
of pulmonary AVMs.
1. Introduction
Humoral immune deficiencies as a group are the most
common type of primary immune disorder. The underlying
etiologyisextremelyvaried,andagrowingnumberofdiverse
genetic mutations have been described [1]. The defect in
antibody production can range from isolated IgA deficiency,
which can be clinically silent, to complete IgG deficiency,
which has been associated with severe infection, requiring
life-long maintenance therapy with IVIG [2]. Combined IgG
subclass deficiencies have also been described. Specifically,
IgA deficiency has been linked to subclass deficiencies in
both IgG2 and IgG4 [3, 4]. Decreased serum levels of IgG2
and IgG4 are sufficient to confer increased susceptibility
to pathogens, particularly those requiring opsonization [4].
IgG2 deficiency has also been independently associated with
the development of lymphoproliferative autoimmune disease
[5].
The epidemiology of humoral immune deficiency is
best characterized for common variable immune deficiency
(CVID) due to its prevalence in the general population.
Outcomes analysis in a cohort of 473 patients with CVID [6]
recently demonstrated noninfectious disease complications
in 68% of patients, which included autoimmune-mediated
cytopenias (thrombocytopenia (14.2%), hemolytic anemia
(7%), and neutropenia (<1%)) and chronic lung disease
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Table 1: The patient had confirmed deficiencies in IgA, IgG2, and IgG4. Immunoglobulin levels are expressed in mg/dL with age-matched
reference ranges provided.
2005 2011 2012
On IVIG No Yes Yes
Trough level No Yes Yes
Low albumin No Yes No
IgG 1240 (639–1344mg/dL) 2540
∗∗ (767–1590mg/dL) 1230 (614–1295mg/dL)
IgG1 960 (422–1292mg/dL) 1730
∗∗ (341–894mg/dL)
IgG2 14










IgM 151 (34–210mg/dL) 591
∗∗ (53–334mg/dL) 125 (53–334mg/dL)
IgE 6 (0–100mg/dL)
∗Abnormally low levels.
∗∗Abnormally high levels. Data are presented from 2005 (before IVIG therapy), 2011 (trough level during IVIG therapy at a time of
hypoalbuminemia), and 2012 (trough level during IVIG therapy at a time of normal serum albumin).
(28.5%).Inpatientswithchroniclungdiseasebronchiectasis,
granuloma formation, and requirement for oxygen were
frequently observed. In contrast, pulmonary AVMs were not
described, and progression to lung transplant was a rare
clinical endpoint (observed in only 3 out of the total 473
patients).
Here we describe a patient with humoral immune defi-
cienciesinIgAandtheIgGsubclassesIgG2andIgG4whohas
beenfollowedupatourinstitutionoverthepastfiveyears.His
initial presentation was pancytopenia, for which he under-
went splenectomy at the age of 18 and subsequent to which
he developed recurrent infections. He was diagnosed with
a “CVID-spectrum disease” elsewhere and started on IVIG
therapy at the age of 20. His course was further complicated
by pulmonary granulomatosis and small pulmonary AVMs,
ultimately requiring bilateral lung transplantation at the age
o f2 5 .Th ep a t i e n ti sa l i v ea n dc o n t i n u e st ob ef o l l o w e da t2 1
months after transplantation.
2. Case Report
The patient was born prematurely at 32 weeks, yet he
did not require neonatal intensive care. In childhood, he
experienced recurrent acute otitis media and mild asthma;
however, he was never hospitalized for a severe pulmonary
d i s e a s eo ri n f e c t i o n .I n2 0 0 2a tt h ea g eo f1 5 ,h ed e v e l o p e d
splenomegaly and cytopenias as follows: neutropenia (gran-
ulocyte antibody positive), anemia (direct antiglobulin test
positive for IgG), and intermittent thrombocytopenia. In
2005 at the age of 18, he underwent splenectomy to thera-
peuticallymanagehiscytopeniasafter a brieftrialofsteroids,
on which he developed shingles. Subsequent to his splenec-
tomy, the patient developed recurrent sinus (requiring hos-
pitalization in 2007), pulmonary (requiring hospitalization
in 2009—cultured positive for H. influenzae,m e t h i c i l l i n -
sensitiveS.aureus,andC.albicans),skin(hospitalizedin2007
for abscess—cultured positive for methicillin-resistant S.
aureus), and central nervous system (hospitalized in 2009—
diagnosed with aseptic meningitis that was presumed viral)
infections.In 2007attheageof20,thepatientwasdiagnosed
with “CVID-spectrum disease” at an outside hospital and
started on IVIG infusions (40g every four weeks). His
immunologicworkup was fragmented prior to 2009 when he
startedtofollowupattheMassachusettsGeneralHospitalfor
routine care.
Chart review of immunoglobulin levels in 2005, prior to
initiation of IVIG therapy, was notable for low age-matched
serum levels of IgA (11mg/dL), IgG2 (14mg/dL), and IgG4
(5mg/dL)withnormalserumlevelsoftotalIgG(1240mg/dL)
and IgM (151mg/dL) (Table 1, “2005”).Postinitiationof IVIG
therapy in 2007, trough levels of IgG2 and IgG4 normalized
(Table 1, “2011”). Of note, intermittent elevations in IgG and
IgM trough levels were observed between 2009 and 2012,
which correlated with times of hypoalbuminemia (Table 1,
comparing “2011” to “2012”). Despite preserved total IgG,
t h ep a t i e n th a dp r o n o u n c e dc l i n i c a lr e s p o n s et oI V I Ga n d
was ultimately maintained on 40g every three weeks to
prevent breakthrough infections. Response to pneumococ-
cal antigen prior to documented Pneumovax in 2005 was
negative per report. Repeat testing was not accomplished
until 2009, at which time 11/23 serotypes remained negative
(1.3mcg/mL being the accepted lower limit reference range
at the Massachusetts General Hospital). Complete blood cell
counts in 2009 were notable for a persistent anemia and neu-
tropenia, with an otherwise preserved differential (Table 2).
Flow cytometry of peripheral blood cells in 2009 (Table 3)
demonstrated a normal number of total T cells (CD3+) and
T cell subsets (CD4+ and CD8+) with CD4−/CD8− cells
accountingfor5%oftotallymphocytesand6%ofCD3+cells,
a finding that could suggest an increase in double-negative T
cells; however, gamma delta T cells cannot be excluded in the
absence of direct TCR𝗼𝗽 staining. Flow cytometry was also
notable for a normal number of total (CD19+) and memory
(CD27+) B cells. However, immunoglobulin staining on the
B cell surface was positive for IgM/IgD and IgM only without
evidence of further class switch, suggesting a B cell matura-
tion arrest at the IgM+/IgD+ stage. T cell function was also
tested in 2009, with notable decreased proliferative responseCase Reports in Immunology 3
Table 2: The patient had confirmed anemia and neutropenia.
Complete blood counts from 2009 expressed as a range and a
median with reference ranges provided.
Range Median Reference











Lymphocytes 1.48–5.78 2.20 1.00–4.80th/𝜇L
Monocytes 1.03–3.63 1.32 0.20–1.20th/𝜇L
Eosinophils 0.00–0.77 0.40 0.00–0.90th/𝜇L
Basophils 0.00–0.42 0.10 0.00–0.30th/𝜇L
∗Abnormally low levels. White blood cells (WBC), hemoglobin (HGB),
hematocrit (HCT), and platelets (PLT) are shown.
to phytohemagglutinin, pokeweed mitogen, tetanus toxoid,
and Candida antigen. In terms of a malignancy workup,
bone marrow biopsy in 2004 demonstrated a normocellular
marrow with trilineage hematopoiesis; lymph node biopsies
i n2 0 0 5a n d2 0 1 1w e r eb e n i g n ,a n ds e r u me l e c t r o p h o r e s i si n
2009 demonstrated minimally elevated levels of free kappa
(31.9 to 95.7mg/L—reference range < 19.4mg/L) and lambda
(40.3to62.6mg/L—referencerange<26.3mg/L)lightchains
withalargelypreservedratio(0.8to2—referencerange<1.7).
Finally, the patient underwent DNA sequencing and analysis
to screen for genetic mutations that have been linked to pri-
mary immune deficiencies, including those associated with
hyper-IgM syndrome (UNG, AICDA, CD40,a n dCD40LG),
CVID (TNFRSF13B (TACI)), X-linked lymphoproliferative
disease (XIAP), and autoimmune lymphoproliferative syn-
drome (ALPS) (CASP8, CASP10, FADD, FAS, FASLG, KRAS,
MAGT1,a n dNRAS). This screening was negative apart from
a hemizygous G-to-A transition at position 655 that was
detected in CD40LG,wh i c hi sp r ed i ct edt ol ea dt oam i s se n se
mutation and is of unknown significance for hyper-IgM
syndrome type 1 [9].
In 2009,his course was complicated by severe hypoxemia
(requiring 6 to 10 liters of supplemental oxygen at baseline
with an arterial partial pressure of oxygen (PaO2)o f6 4m m
Hgandanarterialpartialpressureofcarbondioxide(PaCO2)
of 32mm Hg on room air). Noncontrast computed tomog-
raphy (CT) imaging of the chest demonstrated multiple
nodulesinthebilaterallungfieldsandsignificantmediastinal
lymphadenopathy. Bronchoalveolar lavages (2009 and 2011)
demonstrated rare bacteria and yeast without a consistent
or predominant viral, bacterial, or fungal etiology, and
cytology was without suggestion of malignancy. Quantitative
ventilation/perfusionscanning demonstratedtechnetium-99
localization consistent with right to left pulmonary shunting,
and right heart catheterization was highly suggestive of small
pulmonary AVMs. Follow-up genetic testing for hereditary
hemorrhagictelangiectasia(HHT)byACVRL1andENGgene
sequencing and duplication/deletion analysis was negative.
Of note, SMAD4 was never tested; however, he underwent
endoscopy and colonoscopy in 2009 and again in 2011 that
was without demonstration of gastrointestinal polyps or
gastrointestinal AVMs. Vascular endothelial growth factor
(VEGF) levels were found to be elevated (530pg/mL—
reference range 31 to 86pg/mL), and the patient was started
on a course of suppressive doxycycline therapy.
InJulyof2011,thedecisionwasmadetopursuediagnostic
and therapeutic pulmonary wedge resection. Biopsies of the
right upper and middle lobes demonstrated peribronchiolar
lymphoid hyperplasia that was consistent with humoral
immune deficiency but without clear evidence of vasculitis
or AVMs. By April of 2012, he met criteria for NYHA
Class III-IV functional level and underwent transplantation
evaluation. Considerations for lung transplantation included
arecenthistoryofbiopsy-confirmed(2009and2011)hepatitis
that included a broad differential of autoimmune, viral, and
drug-induced disease etiologies on histopathology. Repeat
liver biopsy in 2012, however, was most suggestive of autoim-
mune hepatitis given the substantial reduction in lobular
lymphoid hyperplasia observed between 2011 and 2012 in
response to a course of suppressive prednisone and azathio-
prine therapy. Of note, his pulmonary function continued to
worsen during this time despite the immunosuppression.
The patient received bilateral cadaveric donor lung trans-
plantation without requirement for cardiopulmonary bypass
on November 21, 2012, at the age of 25. Following surgery,
he received standard of care immunosuppression with three
doses of antithymocyte globulin and two doses of high-
dose methylprednisolone. He was subsequently placed on
a steroid taper and started on tacrolimus (titrated to daily
levels) and azathioprine (150mg daily) with appropriate
antiviral (donor CMV negative, recipient CMV positive),
antibacterial,andantifungalprophylaxis.Hewassuccessfully
extubated by postoperative day three. Repeat pulmonary
function tests and ventilation/perfusion scan demonstrated
excellent function of the transplanted organs without early
concern for mechanical failure. He was discharged home on
postoperative day 15. Subsequent analysis of explanted lung
tissue confirmed the diagnosis of small pulmonary AVMs
with peripherally localizing lymphoid nodules (Figure 1).
At the 21-month follow-up from transplantation, the
patient continues on tacrolimus, prednisone, and sirolimus
for immune suppression (switched from mycophenolate
mofetil secondary to leukopenia). His posttransplantation
course has been complicated by lymphocytic small airway
inflammation and minimal acute rejection on serial graft
biopsies. More recently (June of 2014), he began to develop
accelerated bronchiolitis obliterans syndrome that is cur-
rently being managed with extracorporeal photopheresis.
He additionally continues on IVIG infusions (40g every




and confirmed humoral immune deficiency, which does
not meet criteria for CVID given the preserved level of4 Case Reports in Immunology
Table 3: The patient had preserved populations of total T cells, T cell subsets, total B cells, and memory B cells. There was question of an
elevated double-negative T cell population that was not confirmed on direct TCR𝗼𝗽 staining. Flow cytometry analysis of peripheral blood
cells in 2009.
Major antigen Minor antigen Measured (cells/mm
3) Reference range (cells/mm
3) % of total % of CD3+ % of CD19+
Tc e l l s
CD3+ 4092 690–2540 86% 100%
CD3+ CD4+ 3072 419–1590 64% 75%
CD3+ CD8+ 785 190–1140 16% 19%
CD3+ CD4−/CD8− 235 5% 6%
Bc e l l s
CD19+ 352 90–660 7% 100%
CD19+ CD27+ 107 2% 30%
CD19+ CD27− 245 5% 70%
NK cells CD16+/56+ 335 90–590 7%
Data are presented in cells/mm
3 or % with reference ranges provided (note that reference ranges for CD4−/CD8− cells, CD27+ cells, and CD27− cells are not












Figure 1: Small pulmonary AVMs (򳲳) with peripherally localizing lymphoid aggregates (∗) were confirmed on explanted lung pathology.
Immunohistochemical staining directed against (a) H/E, (b) CD4, (c) CD8, (d) CD20, and (e) CD68.Case Reports in Immunology 5
total IgG (Table 1). Despite the splenomegaly, autoimmune-
mediated cytopenias, and question of an elevated double-
negative T cell population (Table 3), the patient screened
negative for ALPS on gene sequencing and analysis and
otherwise does not fit the full ALPS presentation given the
preserved population of memory B cells, the defect in T cell
proliferation, and the normal levels of total IgG and IgM in
thiscase[7].Therefore,weareleftwithadiagnosisofhumoral
immune deficiency, specific to IgA, IgG2, and IgG4. While
the noted humoral deficits could certainly have predated
the patient’s splenectomy in 2005, this hypothesis was never
validated on laboratory testing and certainly a description
of recurrent infections is not clearly documented at this
time in the patient’s history. Alternatively, the humoral
d e fi c i t sc o u l dh a v ed e v e l o p e ds u b s e q u e n tt ot h ep a t i e n t ’ s
splenectomy. Overall, humoral immune deficiency is known
to be associated with autoimmune-mediated cytopenias. In a
retrospective chart review of 326 CVID patients [10],11%had
a history of autoimmune-mediated cytopenias, 54% of which
had the first episode of thrombocytopenia or hemolytic ane-
mia prior to the diagnosis of CVID. However, postsplenec-
tomy immune deficiency has also been described. In an
analysisof12patientswhounderwenttraumaticsplenectomy
[11], decreased B cell activation was observed in response
to polyclonal activator pokeweed mitogen at two days to
seven years postoperatively. Coculture analysis further con-
firmed that the defect was associated with both the T helper
cell and the intrinsic B cell compartment of the splenec-
tomized patient. In a more recent comparative analysis of
209 asplenic or hyposplenic adults compared to 140 healthy
controls [12], similar total levels of B cells were described.
In comparison to the healthy controls, however, the splenec-
tomized patients had a significant reduction (𝑃 < 0.001)
in memory B cells, including both IgM memory B cells and
switched memory B cells. Consistent with these data, here
we describe preservation of total B cell counts, but with
maturation arrest at the IgM+/IgD+ stage of development.
Furthermore, genetic testing for known mutations linked to
B cell maturation arrest was negative. Therefore, it remains
uncertain as to whether the patient had a humoral immune
deficiency prior to splenectomy or whether the splenectomy
itself initiated a B cell dysregulation. Together these data
highlight the importance of screening for humoral immune
deficiencies concurrent with the diagnosis of autoimmune-
mediated cytopenia and prior to splenectomy and initiation
of the perisplenectomy vaccination series.
Pulmonary complications including granulomas,
bronchiectasis, and emphysema are known to be associated
with primary humoral immune deficiencies [6]. However,
pulmonary AVMs are not a frequent complication of
humoral immune deficiency, as described in chart [6]o r
even direct radiographic [13]r e v i e w .T oo u rk n o w l e d g e ,
there are only two case reports linking humoral immune
deficiency to pulmonary AVMs, described in a patient
with hypogammaglobulinemia [14]a sw e l la sI g Aa n dI g G
subclass deficiency [15]. We also entertained the possibility
that splenectomy itself could have driven the pulmonary
pathology in this case. While postsplenectomy pulmonary
hypertension driven by chronic thromboemboli has
been described [16], our patient had no evidence of
pulmonary hypertension on right heart catheterization
in 2009, and furthermore pulmonary AVMs are not a
known complication after splenectomy [17, 18]. Alternative
diagnoses were entertained in consultation with the medical
genetics team at Massachusetts General Hospital. However,
the patient screened negative for the genetic mutations
most frequently associated with HHT (ACVRL1 and ENG).
Furthermore, HHT is not commonly associated with the
humoral immune deficiencies otherwise described in this
case [19]. Given that the pulmonary AVMs were diffuse and
small in nature, the patient was not an appropriate candidate
for embolization, and he did not clinically benefit from
the pulmonary wedge resection. Ultimately the explanted
lung pathology confirmed prominent and diffuse AVMs
with small surrounding lymphoid nodules (Figure 1). It
is unclear if the lymphocytes were driving the vascular
pathology in this case. However, the physiology is clear,
remarkable for oxygen-resistant hypoxemia with worsening
ventilation/perfusion mismatch as the driving etiology for
transplantation.
Lung transplantation in patients with humoral immune
deficiency is a rare therapeutic endpoint. Several case reports
have been described in patients with panhypogammaglob-
ulinemia for the indications of end-stage bronchiectasis,
emphysema, and/or granulomatous disease [20–23]. Lung
transplantation has also been described in a single patient
with IgG1 subclass deficiency, who was transplanted for the
indicationofend-stagebronchiectasisandwasstillaliveatthe
nine-yearfollow-up[24].Casereportsoflungtransplantation
for the indication of diffuse pulmonary AVMs have also been
described. Of note, these case reports are limited to patients
with a confirmed diagnosis of HHT [25–28]. Therefore,
while it is unclear whether the immune deficiencies herein
described predisposed the patient to pulmonary AVMs, this
is a unique case description of bilateral lung transplantation
for the indication of pulmonary AVMs in a patient without a
confirmed diagnosis of HHT but with a confirmed diagnosis
of humoral immune deficiency.
IVIG is an important component of posttransplantation
management, as hypogammaglobulinemia can be observed
in an immunologically competent patient in the context
of immunosuppressive therapy. In solid organ transplan-
tation, a significant reduction in risk for infection was
recently described with IVIG replacement of approximately
500mg/kg monthly [29]. In our patient, this calculates to
32g of IVIG monthly, which is less than the actual 40g of
IVIG that he has been receiving every three weeks. However,
much of the management of humoral immune deficiency,
especially in the context of solid organ transplantation,
remains elusive. For example, while an anti-infective role
f o rI V I Gi nt r a n s p l a n t a t i o nh a sb e e nd e s c r i b e d[ 29], the
immune-modulatory effects of IVIG are still only partially
understood. Additionally, we lack the long-term follow-
up necessary to investigate whether patients with humoral
immunedeficiencyareatriskofdevelopingrecurrentdisease
in their transplanted organs.
A growing body of data demonstrates the benefit of
hematopoietic stem cell transplantation for the treatment6 Case Reports in Immunology
of primary immune deficiency. Survival and cure after
transplantation in the context of a well-matched donor,
limited infectious disease complications, and no known end-
organ damage has reached 90% [30]. For CVID specifically,
allogeneic stem cell transplantation was recently described
in a cohort of four patients for the indication of malignancy
(twopatients)andsevereend-organfailurewithdocumented
granulomatous disease (two patients) [31]. Three of the four
patients had long-term survival (between 4.5 and 7 years).
However, only one in four patients demonstrated sustained
IgG normalization with adequate vaccine response after
transplantation, suggesting a true cure for CVID. In patients
with primary immune deficiency and end-stage lung disease,
a current clinical trial is underway that will directly address
whetherbilateralorthotopiclungtransplantationfollowedby
cadaveric partially matched hematopoietic stem cell trans-
plantation is safe and effective [32], a proof of principle case
report having already been demonstrated in 2011 [33]. These
data will play a critical epidemiologic role, furthering our
understandingofcotransplantationriskandlong-termbene-
fit and ultimatelydirectingsuperior management of humoral
immune deficiency and its pulmonary complications.
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